These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 1149447)
1. The drug approval process and the FDA. Schmidt AM Conn Med; 1975 Apr; 39(4):237-40. PubMed ID: 1149447 [No Abstract] [Full Text] [Related]
2. Development and approval of vaccines in the United States. Botstein P Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047 [TBL] [Abstract][Full Text] [Related]
3. Washington Report. Drug Regulation Reform. Greenberg DS N Engl J Med; 1978 Apr; 298(17):979-80. PubMed ID: 642986 [No Abstract] [Full Text] [Related]
4. The FDA and "privatization"--the drug approval process. Rutherford EM Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044 [No Abstract] [Full Text] [Related]
5. An interview with FDA Commissioner Frank Young. Interview by Carmella Bocchino. Young FE Nurs Econ; 1989; 7(5):242-8. PubMed ID: 2812067 [TBL] [Abstract][Full Text] [Related]
6. A strike against preemption. Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422 [TBL] [Abstract][Full Text] [Related]
7. Antiarrhythmic drug approval--an industry perspective. Jacobs S Can J Cardiol; 1991; 7(1):45-6; discussion 49-50. PubMed ID: 2025792 [No Abstract] [Full Text] [Related]
8. Evaluation of drugs by the medical letter. Abramowicz M Am J Hosp Pharm; 1976 Jan; 33(1):71-3. PubMed ID: 1266869 [TBL] [Abstract][Full Text] [Related]
9. Advising under the influence?: conflicts of interest among FDA advisory committee members. Glode ER Food Drug Law J; 2002; 57(2):293-322. PubMed ID: 12437003 [No Abstract] [Full Text] [Related]
10. Professional responsibilities. Jenkins WL J Am Vet Med Assoc; 1993 May; 202(10):1742-3. PubMed ID: 8514601 [No Abstract] [Full Text] [Related]
11. Unapproved uses of approved drugs: The physician, the package insert, and the FDA. Pediatrics; 1978 Aug; 62(2):262-4. PubMed ID: 693165 [No Abstract] [Full Text] [Related]
12. The history and contemporary challenges of the US Food and Drug Administration. Borchers AT; Hagie F; Keen CL; Gershwin ME Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043 [TBL] [Abstract][Full Text] [Related]
13. Drug regulation and policy formulation. Nightingale SL Milbank Mem Fund Q Health Soc; 1981; 59(3):412-44. PubMed ID: 7024847 [TBL] [Abstract][Full Text] [Related]
15. The Food and Drug Administration's requirements for approval of new dental drugs. Gilkes CC Symp Pharmacol Ther Toxicol Group; 1975 Apr; ():5-12. PubMed ID: 1064180 [No Abstract] [Full Text] [Related]
16. Knowledge is power: legislative control of drug industry trade secrets. O'Reilly JT Spec Law Dig Health Care (Mon); 1987 May; 8(15):7-31. PubMed ID: 10281981 [No Abstract] [Full Text] [Related]
17. Implementation of the mutual recognition agreement between the United States and the European Community; pharmaceutical GMP's and medical devices; establishment of a public docket and FDA contact points. Food and Drug Administration, HHS. Establishment of a public docket and FDA contact points. Fed Regist; 1999 Mar; 64(45):11376-7. PubMed ID: 10557625 [TBL] [Abstract][Full Text] [Related]
18. The impact of FDA reform. Trunzo J Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699 [TBL] [Abstract][Full Text] [Related]
19. FDA user fees and innovation. Somberg J Am J Ther; 2008; 15(2):97. PubMed ID: 18356626 [No Abstract] [Full Text] [Related]
20. Drug approval process and FDA. Schmidt AM N Y State J Med; 1976 Nov; 76(12):2039-42. PubMed ID: 1069200 [No Abstract] [Full Text] [Related] [Next] [New Search]